Enkephalins, a group of small peptides with opiate-like activity, have been defmied originally as neuropeptides. Recent reports showed, using in situ hybridization, that the enkephalin-encoding gene, proenkephalin A (pEnkA), is expressed in nondifferentiated cells of diverse mesodermal lineages. The transient expression of pEnkA in these tissues during organogenesis suggests that this gene is involved in processes such as differentiation and/or cell proliferation. In situ hybridization revealed that bone and cartilage are among the tissues that express pEnkA most actively during organogenesis. Here we show that pEnkA mRNA is abundant in normal calvaria-derived cells and in osteosarcoma-derived cell lines ROS 17/2.8 and ROS 25/1. In addition, pEnkA-derived peptides are synthesized and secreted by these cells, as revealed by specific RIA. pEnkA expression in ROS cells is decreased by osteogenin, an osteoinductive factor, and by the calciumregulating hormone, 1,25-dihydroxyvitamin D3, whereas the osteoblastic phenotype marker, alkaline phosphatase, is increased by these factors. These results together with the inhibitory effects of pEnkA-derived peptides on alkaline phosphatase activity in ROS 17/2.8 cells suggest that pEnkA is involved in bone development and provide a model system for further analysis of pEnkA expression during this process. . From their numerous actions in the nervous and endocrine systems (such as analgesia and responses to stress and pain), enkephalins have been defined as neurotransmitters, neuromodulators, and neurohormones. Until recently the pEnkA gene was considered to be mainly expressed in the mature nervous and neuroendocrine systems (4-6). However, more recently it has become evident that pEnkA is expressed in other systems as well (7-12). For example, we showed that pEnkA is expressed in nondifferentiated cells of diverse mesodermal lineages. This expression is defined by a time interval corresponding to organogenesis and early postnatal development and mostly occurs within mesenchymal derivative tissues (13, 14) . Strikingly high levels of pEnkA mRNA were detected in the cartilaginous and bone primordia preceding terminal differentiation. These observations suggested that pEnkA plays a regulatory role associated with cell proliferation and/or differentiation of mesodermal lineages, including bone and cartilage (13).
involved in bone development and provide a model system for further analysis of pEnkA expression during this process.
The proenkephalin A (pEnkA) gene encodes a family of structurally related opioid peptides. Proteolytic processing of the pEnkA precursor protein generates a group of small neuroendocrine peptides, such as [Met]-and [Leu]enkephalin, [Met] enkephalin-Arg-Phe, [Met] enkephalin-Arg-GlyLeu, and [Met] enkephalin-Arg-Arg-Val (1) (2) (3) . From their numerous actions in the nervous and endocrine systems (such as analgesia and responses to stress and pain), enkephalins have been defined as neurotransmitters, neuromodulators, and neurohormones. Until recently the pEnkA gene was considered to be mainly expressed in the mature nervous and neuroendocrine systems (4) (5) (6) . However, more recently it has become evident that pEnkA is expressed in other systems as well (7) (8) (9) (10) (11) (12) . For example, we showed that pEnkA is expressed in nondifferentiated cells of diverse mesodermal lineages. This expression is defined by a time interval corresponding to organogenesis and early postnatal development and mostly occurs within mesenchymal derivative tissues (13, 14) . Strikingly high levels of pEnkA mRNA were detected in the cartilaginous and bone primordia preceding terminal differentiation. These observations suggested that pEnkA plays a regulatory role associated with cell proliferation and/or differentiation of mesodermal lineages, including bone and cartilage (13) .
The bones of the body are of different physical shapes, lengths, and cellular origin. The cellular and molecular embryology of bone formation is detailed in a recent review (15) . That osteoid synthesis and matrix mineralization are important factors in the process is evident. The osteoblasts synthesize the organic matrix and help its mineralization (16) .
Various models have been developed to study osteoblast physiology in vitro. These models include primary cell cultures and transformed and nontransformed cell lines derived from bone. These bone cells in culture share common phenotypic features: elevated alkaline phosphatase levels, parathyroid hormone-responsive adenylate cyclase, and synthesis of mainly type I collagen (16) . The mesenchymal origin of the osteoblasts and their role in bone development make them a candidate for a model in which to study pEnkA involvement in this process.
In this work, we report that the pEnkA gene is abundantly expressed in normal and transformed osteoblastic cells and is regulated by factors affecting the osteoblast phenotype, suggesting a role for pEnkA-derived peptides in osteogenesis.
MATERIALS AND METHODS
Cell Cultures. The rat osteosarcoma-derived cell lines ROS 17/2.8 and ROS 25/1 (16, 17) and the human osteosarcomaderived cell line Saos-2 (18) were cultured in RPMI 1640 medium/10% fetal bovine serum (FBS)/penicillin/streptomycin. The mouse calvaria-derived cell line MC 3T3/E1 (19) was cultured in a-modified Eagle's medium/10% FBS/ penicillin/streptomycin. Cells were routinely subcultured once a week. Primary cultures of bone cells were obtained by collagenase (Worthington) digestion of 20-to 21-day-old embryonic Sabra rat calvaria (20) . Five sequential digestion steps of 20 min each were performed. Cells released from the first, two digestions and cells released from the last two digestions were pooled to obtain fractions I and II, respectively. Cells released from the third digestion were discarded. Cells were plated in Dulbecco's modified Eagle's medium/ 10% FBS/penicillin/streptomycin (0.5 x 106 per 10-cm dish). Secondary cultures were obtained by releasing the cells from the dishes with trypsin/EDTA. Media and sera were purchased from Biological Industries, Beth Haemek, Israel.
Alkaline Phosphatase. Alkaline phosphatase activity was measured by a modification of the method of Absolom (21) . Cells (1000-3000 per well) were plated onto 96-well plates (Costar). Before the assay the monolayer was washed three times in phosphate-buffered saline (PBS). The wells were air-dried, and 50 ,l of deionized water was added. The plates were frozen and thawed, and substrate solution was added to the wells (50 ,ul of 9 mM p-nitrophenyl phosphate Triton/0.2 M diethanolamine hydrochloride buffer, pH 9.75/0.1% Triton X-100 tTo whom reprint requests should be addressed.
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. Kaiser and U. Fischer, Hoffmann-La Roche), and pEnkAderived peptides (Sigma) were tested, the cells (3000 per well) were plated in RPMI 1640 medium/10% FBS. Forty-eight hours later, monolayers were washed three times with PBS, and the tested agent was added to the wells in RPMI 1640 medium containing bovine serum albumin at 5 mg/ml. Experiments were performed in quadruplicates. In parallel plates, cells were seeded for protein determination (23) , which was also performed in the wells and analyzed in ELISA reader.
Hybridization Probes. The pDR1014 plasmid contains a 417-base-pair (bp) Pst I fragment that begins 21 bp downstream from the start of exon III of the rat pEnkA gene that was cloned into a pBS vector (Stratagene) (14) . pDR1014 was linearized by digestion with the appropriate restriction endonuclease to allow synthesis of a 35S-labeled RNA probe in either the antisense or the sense orientation using T3 or T7 polymerase, respectively. RNA probes were used for in situ hybridization analysis. For RNA blot analysis, 32P-nick translated DNA probes, derived from the same plasmid ofnot less than 5 x 108 cpm/,g ofDNA, were prepared.
Isolation and Blot Analysis of RNA. Total RNA was extracted from cells according to the method described by Chirgwin et al. (24) . Analysis of total RNA was done as described (14) . Relative mRNA levels of the autoradiograms were measured by densitometry.
In Situ Hybridization Analysis. In situ hybridization was done by the method of Hogan et al. (25) with modifications. ROS 17/2.8, ROS 25.1, and calvaria-derived (fraction II) cells were grown on glass slides precoated with poly(L-lysine). Exponentially grown cultures were fixed in 4% (wt/vol) paraformaldehyde, dehydrated in graded ethanol solutions, and stored at -20'C for later use. Before hybridization the cells were successively pretreated with 0.2 M HCl/2 x standard saline citrate (SCC) (1x SSC is 0.15 NaCl/0.015 sodium citrate, pH 7), lx PBS/4% paraformaldehyde and acetic anhydride/triethanolamine buffer. Hybridization occurred at 500C overnight in 50% (vol/vol) formamide/0.3 M NaCI/10% dextran sulfate/i x Denhardt's solution/carrier tRNA at 1 mg/ml/10 mM dithiothreitol/5 mM EDTA containing 35S-labeled RNA probe at 2 x 108 cpm/ml. After hybridization the slides were washed under stringent conditions that included incubation at 50'C for >12 hr in 50% formamide/0.3 M NaCl and 40 min at 370C RNase A at 20 gg/ml (Sigma).
Autoradiography was performed with Kodak NTB-2 nuclear track emulsion and developed after 3-4 days of exposure.
Isolation and Analysis of Peptides. Cells and culture media were processed and analyzed for the presence of immunoreactive (ir) [Metlenkephalin and enkephalin-containing peptides using a proteolytic digestion protocol and described RIA (8 calvaria-derived osteoblastic line MC3T3/E1 was done as described. Autoradiograms of this analysis show that normal calvaria cells (secondary cultures of fractions I and II, fibroblastic and preosteoblastic enriched cells, respectively) and the ROS cell lines express a 1.4-kilobase (kb) pEnkA mRNA, whereas no hybridization signals were observed in Saos-2 and MC3T3/E1 (Fig. 1) . After longer exposure times (72 hr), residual pEnkA mRNA-specific signals were detected in the human and mouse lines (data not shown). Note that the levels of pEnkA mRNA in the calvaria-derived and the ROS cells are higher than in the hypothalamus. The examined cells did not express the other opioid-encoding genes, proopiomelanocortin and prodynorphin, which, as expected, were expressed in the hypothalamus. Hybridization with 8-tubulin cDNA probe verified the quality and the relative amounts ofthe RNA loaded in each lane. Remarkably, ROS 25/1 showed much higher levels (20-fold) of expression than ROS 17/2.8. In situ hybridization was used to examine the pEnkA-expressing cell fractions. By using a 35S-labeled antisense pEnkA RNA probe, high levels of pEnkA mRNA were detected in -95% of ROS 25/1 cells, whereas only -3O3% of ROS 17/2.8 cells expressed the gene (Fig. 2 A and C) . In situ hybridization analysis of the preosteoblast-enriched fraction from rat calvaria revealed that -85% of the cells expressed pEnkA gene (Fig. 3A) Modulation of pEnkA Expression in ROS Cells. To determine whether pEnkA expression is regulated by factors affecting osteoblastic phenotypes, we used ROS cell lines, a widely known model, to study osteoblastic properties. Fig. 4 shows that a decrease in pEnkA mRNA levels was seen after treatment of ROS 17/2.8 cells with rat-derived osteogenin. Smaller but significant changes were seen in cells treated with the active metabolite of vitamin D3, 1,25(OH)2D3. Densitometric tracing of the autoradiograms shown in Fig. 4 indicated a marked inhibition in the pEnkA mRNA levels seen in osteogenin-treated cells relative to control (Fig. SA) . Osteogenin at 2 and 10 ,g/ml caused a 3-and 5-fold decrease, respectively. No significant effect was seen with 0.2 ,ug/ml. 1,25(OH)2D3 reduced pEnkA mRNA levels up to 50%. Parallel examination of alkaline phosphatase activity in these cells showed dose-dependent enhancement by osteogenin and 1,25(OH)2D3 (Fig. SB) cells. As seen in Table 2 , 48-hr incubation of ROS 17/2.8 cells with these peptides resulted in a dose-dependent decrease (up to 50%) of alkaline phosphatase activity. Significant effects were already seen by using 10-10 M of the peptides. Dynorphin A, an opioid derived from the prodynorphin gene, and the opiate morphine had no effects on alkaline phosphatase activity.
DISCUSSION
In contrast to the original concept, it is well recognized now that sites of enkephalin synthesis are not limited to the nervous system (7) (8) (9) (10) (11) (12) (13) (14) . Recent reports showed that pEnkA is widely expressed in cells of diverse mesodermal lineages during organogenesis, suggesting a general regulatory role for pEnkA in development (13, 14, 26) . Bone and cartilage are among the most abundantly pEnkA-expressing mesodermal tissues (13) . These findings prompted us to explore the possible role(s) of pEnkA-derived peptides in bone development.
In the present study, we used fetal rat calvaria cells and rat, mouse, and human-derived osteoblastic cell lines. pEnkA mRNA, but not prodynorphin or proopiomelanocortin, was expressed in the bone-derived cells (Figs. 1-3) . pEnkA mRNA levels in the calvarial cells and ROS cell lines were higher than in hypothalamus. The high levels of pEnkA mRNA detected in >85% of the normal preosteoblasts make this model system suitable for molecular examination of pEnkA expression in osteogenesis. Moreover, the ability of both calvaria-derived preosteoblasts and ROS cell lines to synthesize and secrete pEnkA-derived peptides ( Fig. 4 (Figs. 4 and 5 ). This reciprocal relationship supports our previous observations, indicating that pEnkA mRNA is localized in bone primordia preceding terminal differentiation (13) . In addition, these results suggest that pEnkA-derived peptides modulate alkaline phosphatase activity in these cells. Therefore, assessing the effects of osteoblastic pEnkA-derived peptides, once characterized, on osteoblastic phenotypes would be of interest. As an initial step, we tested the influence of known opioid peptides and ited the activity of alkaline phosphatase, whereas the other opiates morphine and dynorphin A had no effect (Table 2) . It is noteworthy that only pEnkA-derived peptides, and not other opioids, affected the enzyme activity. Although free
[Met]enkephalin was not detected in osteoblast culture media, this peptide exhibited a potent inhibitory effect on alkaline phosphatase activity. This result can be explained by an agonist-like action. To define the function(s) of pEnkA gene products in bone development, it is essential to elucidate their chemical nature. Nevertheless, alkaline phosphatase modulation by the tested peptides supports the notion that pEnkA gene expression is involved in osteoblast differentiation.
In agreement with our previous observations in vivo (13) , we show here that the pEnkA gene is expressed in bonederived cells. The abundance of pEnkA mRNA and peptides in osteoblastic cells, pEnkA mRNA modulation in osteoblasts, and the effects of pEnkA-derived peptides on these cells strongly supports the hypothesis that pEnkA gene expression plays a significant role in bone development.
